A spotlight on Gastric Neuroendocrine Neoplasms

Translate
Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 19,501 other subscribers.

What are Gastric NENs

Unlike other anatomical types, the word Gastric is used to indicate a tumour (NET) or carcinoma (NEC) in the stomach.  The stomach lies at the bottom of your oesophagus and connects to the first part of the small intestine (the duodenum).  Clearly a key part of the gastrointestinal system, it processes food on its journey downwards.

The stomach produces strong acid. This kills many microorganisms that might have been swallowed along with the food. It also contains special chemicals called enzymes. These are important for breaking down the food so it can be absorbed by the body. After it leaves the stomach, the partially digested food passed into the intestines where it begins to be absorbed.

The main parts of the stomach are shown below (often this can give clues about the type):

Diagram of basic surface anatomy and regions of the stomach. Drawn in Inkscape. Based on diagram from Moore, K.L., & Agur, A.M. (2007). Essential Clinical Anatomy: Third Edition. Baltimore: Lippincott Williams & Wilkins. 145. ISBN 978-0-7817-6274-8

Epidemiology

Gastric neuroendocrine neoplasms (gNENs) are not as common as most other types of NET with multiple observational studies showing that they account for approximately 8% of all digestive NENs and less than 1% of all gastric neoplasms. However, the incidence of gNENs has increased in most countries over recent decades, in part because of greater awareness of the disease among clinicians, improved diagnostic techniques and more widespread use of upper gastrointestinal endoscopy.  Percentages by type are given below where known.  Mixed Cell tumours, i.e. Mixed Neuroendocrine Non-Neuroendocrine Neoplasms (MINEN) are possible. 

General point about gastric polyps.  Gastric polyps are often found incidentally on endoscopy. A one-year study conducted in the United States on 120,000 patients showed a 6% prevalence of gastric polyps found on upper endoscopy. About 70% to 90%, are hyperplastic polyps or fundic polyps. Hyperplastic polyps are asymptomatic, found incidentally, rarely carry malignant risk, and occur in the setting of chronic inflammatory conditions or H. pylori infection. In the United States and other western countries, fundic gland polyps are most common due to proton pump inhibitor (PPI) use (see below) and low prevalence of H. pylori infection. These also are unlikely to progress to malignancy.  Only a biopsy can confirm if a polyp is a NEN.

Types of Gastric NENs

Like many parts of the anatomy, NENs are categorised due to their heterogenous nature. Currently there are 3 main types of gNENs ranging from indolent types up to a type with the potential to be particularly very aggressive.  I will also mention a fourth type which is starting to appear in many articles.  The types are not always correlated with stage or grade

Type I

Comprising between 70 and 80% of all Gastric NENs, type I tends to be confined to the stomach and act in an indolent manner.  They are heavily associated with Chronic atrophic gastritis (CAG), Autoimmune CAG, pernicious anaemia (an autoimmune condition) and achlorhydria (a condition in which the stomach does not produce hydrochloric acid).

Can present with single or multiple tumours normally less than 1cm in size are polypoid or submucosal growths. 

Type I gNETs occur in response to hypergastrinemia (elevated fasting serum gastrin levels) in the setting of achlorhydria (gastric pH > 4) typically seen in autoimmune CAG where gastric parietal cells in the gastric body and fundus are destroyed by an autoimmune process. 

Mainly found in the body and fundus. Risks of metastases very low at between 2 and 5%.

Type II

Comprising between 5 and 10% of all Gastric NETs and much misunderstood within the NET community.  This type also presents in a setting of hypergastrinemia (elevated fasting serum gastrin levels) but unlike Type I, with hyperchlorhydria (gastric pH ≤ 2) and hypertrophic mucosa.  Can present often with multiple tumours normally less than 2cm in size.

However, in a Type II gNET, the excessive gastrin is being released from a secondary source such as from a gastrinoma in the pancreas or duodenum (Zollinger-Ellison syndrome), i.e. an existing NET.  They are often associated with MEN1, rarely with sporadic ZES. 

Type II gNETs  are mainly found in the body, fundus and antrum of the stomach. Risk of metastases is much higher than type I with between 10 and 30% chance, so generally still a good outlook.

Type III

These are heterogenous type of gNEN which can occur sporadically and in large single tumours greater than 2cm.  They are normally not related to hypergastrinemia or achlorhydria/hyperchlorhydria with normal levels of Gastrin and pH. Their heterogeneity means they can be any of the 3 well differentiated NET grades or a Neuroendocrine Carcinoma (NEC) which is poorly differentiated by default.  Most type III are however, grade 3.  The risk of metastases is high between 50 and 100%.

Type IV Proposals

In addition to these classical three subtypes, the existence of a type IV gNEN has been suggested.

One proposition has been that this fourth type has similar characteristics to type III gNENs, but an even more aggressive nature. This type of gNEN may arise from other types of endocrine cells and be a poorly differentiated NEC. In modern NEN classification systems, however, it is likely that this type of type IV gNEN simply represents a type III gNEN which has features of a NEC rather than a NET.

A second different proposal for a type IV gNEN involves a gNEN that has developed in a patient who has an intrinsic defect in the secretion of acid by gastric parietal cells. This type of type IV gNEN is characterised by hypochlorhydria, hypergastrinaemia and multiple small gastric polyps (similar to type I), but histological examination of the gastric corpus mucosa classically reveals hypertrophy and hyperplasia of parietal cells, with a vacuolated cytoplasm suggesting a structural abnormality that prevents acid secretion. This type of gNEN is very rare, and the mechanism of pathogenesis is similar to type I, so it is not frequently included as a separate entity in gNEN classification systems.

What is Gastrin?

Gastrin is a hormone secreted by G cells in the stomach lining. At physiological concentrations, gastrin controls gastric acid production, and repairs and maintains the stomach lining. 

When we eat food, G cells release gastrin into the bloodstream. Gastrin stimulates gastrin receptors (also called CCK2 receptors, CCK2 R) on enterochromaffin-like (ECL) cells in the stomach lining to release histamine, which in turn stimulates histamine H2-receptors (H2R) on adjacent parietal cells (acid-producing cells) to secrete acid into the stomach via the proton pump in the parietal cells. As acid rises, and food passes out of the stomach, it switches on D cells in the stomach lining to release another hormone, somatostatin, which enters the bloodstream and switches off gastrin production by the G cells

What is Hypergastrinemia?

Anything that reduces gastric acid production (hypoacidity) results in persistently increased blood levels of gastrin (hypergastrinemia), which leads to: irregular gene expression in cells of the stomach lining; increased growth of those cells and their potential to metastasise (spread); and reduced apoptosis (natural cell death). All of those effects increase the risk of malignancy.

The main causes of hypoacidity and hypergastrinemia are:

  • Autoimmune chronic atrophic gastritis (CAG), a condition in which patients make antibodies against their parietal cells. Hypergastrinaemia causes growth of ECL cells and, in some patients, formation of multiple gastric neuroendocrine tumours (gNETs). 
  • Inflammation of the stomach lining by infection with H. pylori bacteria. A study in an animal model has shown that hypergastrinaemia is the cause of the inflammation. H. pylori is also the main cause of stomach ulcers and gastric cancer.
  • Medicines that suppress acid production, such as a proton pump inhibitor (PPI) or potassium-competitive acid inhibitor and are mainly used to treat heartburn and indigestion caused by backflow of acid (reflux) from the stomach into the oesophagus (gullet).

What is Pernicious anemia?

Pernicious anemia occurs when your body can’t absorb enough vitamin B12 to function properly. This type of anemia is called “pernicious” because it was once considered a deadly disease. Today, though, it’s relatively easy to treat. While vitamin B12 deficiency anemia may be caused by a lack of vitamin B12 in the diet, pernicious anemia is caused by an inability to absorb vitamin B12. Pernicious anemia can be autoimmune or genetic related.

Syndromes and Gastric NENs

So called ‘carcinoid syndrome‘ is rare in gNENs and any clinical manifestation is atypical consisting exclusively of redness due to histamine production.

Hypoacidity and hypergastrinemia are not carcinoid syndrome, the causes of those symptoms are listed above.

Type II gNET are a secondary effect of excessive gastrin is being released from a secondary source such as a gastrinoma in the pancreas or duodenum i.e. an existing NET outside the stomach.  This existing NET is related to a syndrome known as Zollinger-Ellison syndrome.  Gastrinomas are frequently associated with MEN1, a hereditary NET syndrome. 

Hereditary connections

Nothing observed other than the relationship with Type II and MEN1 already covered under Type II. 

Treatment and Surveillance

The treatment of gNETs depends on the clinical type, disease extent, the differentiation of the lesion and the presence or absence of poor prognostic factors. 

This differs from regional/national guidelines but in general:

Type I gNETs will normally be managed via gastroscopy surveillance with polyp removal when necessary.  B12 supplementation and treatment for iron deficiency anaemia and pernicious anaemia may be necessary. 

Type II gNETs may already have a management system in place for the Gastrinoma and where applicable for MEN1. If the Gastrinoma is considered a causal factor in the gNET, surgery may be considered to remove the Gastrinoma. Endoscopic resection of gastric polyps with gastroscopy surveillance is normally sufficient if no other prognostic factors are present.

Type III gNENs may need more aggressive treatment including surgery and chemotherapy where applicable. 

So called ‘carcinoid syndrome‘ is rare in gNENs and any clinical manifestation is atypical consisting exclusively of redness due to histamine production.  

The use of somatostatin analogues (SSA) for localised gNENs is generally not required although some Type II gNETs may already be established on SSAs.  Guidelines say they should be considered in metastatic cases and for Type II gNET if not already established. 

What are Proton Pump Inhibitors?

Proton pump inhibitors (PPIs) are among the most commonly used medications in the world. They reduce the production of acid by blocking the enzyme in the wall of the stomach that produces acid. Acid is necessary for the formation of most ulcers in the oesophagus, stomach, and duodenum, and the reduction of acid with PPIs prevents ulcers and allows any ulcers that exist in the oesophagus, stomach, and duodenum to heal. PPIs are prescribed to treat acid-related conditions such as:

  • Esophageal, duodenal and stomach ulcers
  • NSAID-associated ulcer
  • Ulcers
  • Gastroesophageal reflux disease (GERD)
  • Zollinger-Ellison Syndrome – ZES (note this is a syndrome associated with a functioning duodenal or pancreatic NET known as a Gastrinoma)
  • They also are used in combination with antibiotics for eradicating Helicobacter pylori, a bacterium that together with acid causes ulcers of the stomach and duodenum for eradicating H. pylori, a bacterium that together with acid causes ulcers of the stomach and duodenum.

The PPI connection

This continues to be a controversial area.  It is already well known that PPI use causes elevation of the gold standard NEN tumour marker Chromogranin A to the point that many doctors no longer use this test.  There are several other potential causes of elevation but PPI is the most common given its wide use in the general population.

More controversial is the suggestion that hypergastrinemia exerts a proliferative effect on ECL-cells in the stomach, leading to linear and micronodular ECL-cell hyperplasia and subsequently dysplasia and NET development.  In the hypoacidic stomach of patients with autoimmune chronic atrophic gastritis (CAG) or mutations of genes controlling acid production, somatostatin production by D cells is not switched on and gastrin production by G cells continues. Hypergastrinemia ensues and causes ECL-cell growth and, in some patients, gNETs, which can be seen at gastroscopy.  Although PPIs also reduce acid production and cause hypergastrinemia, there are only a few case reports of gNETs in patients on long-term PPI therapy. 

Two add-on points.  

One NET clinic has suggested that those taking PPI could be just as well served by migration to Histamine H2 Receptor Antagonists (H2RA) that reduce the amount of acid produced by the cells in the lining of the stomach. They are also commonly called H2 blockers.  This includes a tapering off timeline given the adverse effect of suddenly stopping PPI use.  You can read about a suggested migration strategy by clicking hereYou should NEVER stop taking PPIs without speaking to the doctor who prescribed them.

According to UKINETs, Type I Gastric NETs should preferably stop PPIs as continued use will further increase gastrin and little rationale for ongoing treatment.  You should NEVER stop taking PPIs without speaking to the doctor who prescribed them.

Clinical Trial Drug

Phase 2 clinical trials took place in several countries including UK and Norway.  The manufacture is looking to launch a Phase 3 clinical trial with over 200 participants on an international basis.  Read more here or by clicking on the graphic.

Click to read more

Disclaimer

I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.  Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional as they are not members of the private group or followers of my sites in any official capacity.  Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 19,501 other subscribers.

Thanks for reading.

Ronny

I’m also active on Facebook. Like my page for even more news. Help me build up my new site here – click here and ‘Like’

Sign up for my newsletters – Click Here

Disclaimer

My Diagnosis and Treatment History

Follow me on twitter

Check out my online presentations

Check out my WEGO Health Awards

Like my new awareness page – click here or on the photo.  (Like rather than follow please!)

Check out my Glossary of Terms – click here

patients included

Please Share this post for Neuroendocrine Cancer awareness and to help another patient

 
 
 
Facebook
Twitter
Pinterest
WhatsApp
Email

Nuclidium wins award to study NET radiopharmaceutical – Phase 1 Clinical Trial of TraceNET (TM)

What is TraceNETTM TraceNETTM is a a novel copper-based ‘radiodiagnostic’ for detecting neuroendocrine tumours (NET). The PET imaging agent candidate is the diagnostic component of

Read More »

Experimental drug for Gastric NET – Netazepide

Gastric NETs When I wrote my post entitled “Spotlight on Gastric Neuroendocrine Neoplasms“, I explained what these were with some emphasis on the association with

Read More »

A Newsletter from RonnyAllan.NET – 13th March 2023

Newsletter from Ronny Allan – 13th March 2023 Welcome to my new template newsletter compiled using WordPress (my blog app). This is the 2nd in

Read More »

Fructose intolerance – the NET Effect

Background   When I cast my mind back to my very first surgery, I remember all sorts of ‘plumbing’ issues but was told it would take

Read More »

A tribute to the life and legacy of Miranda Filmer

It’s true to say that Neuroendocrine Cancer is an older person’s disease, the epidemiology is clear on that.  But I do see many young people

Read More »

Treatment for Neuroendocrine Cancer: Beware of the alternatives

The Alternative Hype Cancer Research UK warns of the risks in Alternative Therapies, and I pay great attention to what these guys say.  I know

Read More »

RonnyAllan.NET – Summary of February 2023 – Ronny Allan – Living with Neuroendocrine Cancer

Summary Another great start to 2023 and I thank those who continue to support my social media and this blog.  I’m keen to hear any

Read More »

A spotlight on Gastric Neuroendocrine Neoplasms

What are Gastric NENs Unlike other anatomical types, the word Gastric is used to indicate a tumour (NET) or carcinoma (NEC) in the stomach.  The

Read More »

Sometimes I climb hills just to piss my cancer off

Pissing off cancer is both metaphorical and physical Being diagnosed with a Grade 2 metastatic Neuroendocrine Cancer in 2010 was a bit of a shock.

Read More »

2 thoughts on “A spotlight on Gastric Neuroendocrine Neoplasms

  • Sue Moore

    Hi Ronny, thanks for this article, much appreciated – would it be ok to print a copy to give to my GP?
    I have gastric NETs type 1, but I also have atypical carcinoid syndrome, proven recently by a prolonged episode of carcinoid syndrome on cessation off my prophylactic IV meds 12 hours after surgery; this meant I required 4 sub cut sandostation injections over 24 hours before it abated. Prior to this my specialist suspected it but now it is proven of course and I carry a I.C.E letter with me at all times. My specialist, as you’ve said in the article, has told me it is rare, and that he doesn’t know why I have it. I’ve read a few articles about it but they are thin on the ground.
    Thank you for highlighting this rare possibility as most GP’s know very little about GNETs (or any other NETs for that matter) or carcinoid syndrome, but this article would help my GP to know a little more about my situation, especially from the atypical carcinoid syndrome standpoint.
    Interestingly I was put on high strength PPI’s by my GP (14 years ago) for at least 3 – 4 years, my husband and I eventually worked out that they were making me very ill indeed – I couldn’t eat, couldn’t excrete food or even drink much by the end when I was hospitalised.
    I diagnosed GNet’s myself through reading articles and insisting on a second gastroscopy because of the histology report findings on the first gastroscopy – I was finally diagnosed 5 years ago and my specialist congratulated me on my research and for catching them (GNETs) early.
    I can’t thank you enough for this article.

I love comments - feel free!

%d bloggers like this: